BMO steps to sidelines on Ambit following quizartinib news

|About: Ambit Biosciences Corp (AMBI)|By:, SA News Editor

BMO cuts Ambit Biosciences (AMBI -29.7%) to Market Perform from Outperform.

The shares are struggling mightily today on the heels of Tuesday's quizartinib news.